CDT Equity Inc. (CDT): R&D Expense
$5.05M
Year ended 2025-12-31
$3.36M
Trailing 12 months to 2026-06-30
n/m
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.05M | +49.6% | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | $3.38M | n/m | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | $90.0K | +143.2% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $37.0K | n/a | 2024-04-16, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| CDT Equity Inc. (CDT) | 2025-12-31 | $5.05M | +49.6% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $2.09M | +323.5% |
| AEON Biopharma, Inc. (AEON) | 2025-12-31 | $4.09M | -71.1% |
| Ernexa Therapeutics Inc. (ERNA) | 2025-12-31 | $4.16M | -9.7% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $2.11M | -57.8% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $4.91M | -14.2% |
| Polaryx Therapeutics, Inc. (PLYX) | 2025-12-31 | $6.27M | +122.9% |
| Greenwich LifeSciences, Inc. (GLSI) | 2025-12-31 | $17.22M | +11.2% |
| Petros Pharmaceuticals, Inc. (PTPI) | 2024-12-31 | $2.62M | +8.5% |
Compare CDT, JUNS, AEON, ERNA side by side · Screen every company in Pharmaceutical Preparations ↗